Infectologia

COVID-19: endemia não significa que o risco acabou.

25 Jan, 2022 | 14:58h

COVID-19: endemic doesn’t mean harmless – Nature

---

Diretor geral da OMS | “Vamos conviver com a COVID em futuro previsível; mas podemos acabar com a fase aguda da pandemia este ano.”

25 Jan, 2022 | 14:57h

We Will be Living with COVID for Foreseeable Future; but We Can End Acute Phase of Pandemic this Year — WHO Director General – Health Policy Watch

---

Estudo randomizado | Ertapenem 1.000 mg em dose única é não inferior a ceftriaxona 500 mg em dose única para o tratamento da gonorreia.

25 Jan, 2022 | 14:48h

Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial – The Lancet Infectious Diseases (link para o resumo – $ para o texto completo)

 

Comentário no Twitter (fio – clique para saber mais)

New from @TheLancetInfDis Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial by @henryjdevries and colleagues https://t.co/K2fw5ORNlm pic.twitter.com/d8wz1Vc41Q

— The Lancet HIV (@TheLancetHIV) January 24, 2022

 

---

Estudo de coorte | Em pacientes com prótese articular, a antibioticoprofilaxia provavelmente não é necessária para procedimentos dentais invasivos.

25 Jan, 2022 | 14:39h

Analysis of Prosthetic Joint Infections Following Invasive Dental Procedures in England – JAMA Network Open

Comentário: Prophylactic Antibiotics Not Needed Before Invasive Dental Procedures – HealthDay

 

Comentário no Twitter

Case-crossover study analyzing the incidence of invasive dental procedures (IDP) over the 15-months before 9,427 late prosthetic joint infection hospital admissions (LPJI) and found no evidence of a temporal association b/w IDP and LPJI. https://t.co/hcpwpN0B4H

— JAMA Network Open (@JAMANetworkOpen) January 19, 2022

 

---

Estudo de caso-controle | 3 doses de vacinas de mRNA foram associadas com redução nas infecções pelas variantes Ômicron e Delta do SARS-CoV-2 em comparação com 2 doses ou nenhuma vacinação.

25 Jan, 2022 | 12:07h

Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants – JAMA

Editorial: Booster Vaccination to Prevent COVID-19 in the Era of Omicron: An Effective Part of a Layered Public Health Approach – JAMA

Comentários: New data show booster doses protect against Omicron – CIDRAP

Boosters provide the best protection against Omicron variant, CDC studies show, raising new questions about what it means to be fully vaccinated – CNN

Estudos do CDC relacionados:

COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021 – CDC Morbidity and Mortality Weekly Report

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 – CDC Morbidity and Mortality Weekly Report

 

Comentário no Twitter

Study suggests receipt of 3 doses of mRNA #COVID19 vaccine, vs 2 doses or being unvaccinated, was associated with protection against both the Omicron and Delta variants; higher odds ratios for Omicron suggest less protection for Omicron than for Delta. https://t.co/kOZh0fq5TL

— JAMA (@JAMA_current) January 21, 2022

 

---

CDC da Europa sobre a Ômicron: “Entre os casos de Ômicron reportados ao TESSy, 1,14% foram internados, 0,16% necessitaram de internação em UTI/suporte respiratório e 0,06% morreram.”

25 Jan, 2022 | 12:05h

Weekly epidemiological update: Omicron variant of concern (VOC) – week 2 (data as of 20 January 2022) EU/EEA – European Centre for Disease Prevention and Control (ECDC)

---

Diretriz atualizada | Medicamentos e agentes biológicos recomendados para pacientes adultos com COVID-19.

25 Jan, 2022 | 12:04h

Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19 – Covid-19 Advisory for Ontario

 

Comentário no Twitter (fio – clique para saber mais)

🔥JUST RELEASED: New clinical guidelines for COVID now including #Paxlovid (nirmatrelvir/ritonavir).

A 🧵 on why Paxlovid is NOT first-line.https://t.co/h0puYpiFOK

— Andrew Morris (@ASPphysician) January 22, 2022

 

---

Roteiro atualizado da OMS para priorizar o uso das vacinas contra COVID-19.

25 Jan, 2022 | 12:03h

WHO SAGE Roadmap for prioritizing uses of COVID-19 vaccines – World Health Organization

Comentário: WHO: COVID boosters should start with most vulnerable – Associated Press

 

Comentário no Twitter (fio – clique para saber mais)

UPDATED: The Strategic Advisory Group of Experts (SAGE) have revised the Roadmap for Prioritising Uses of #COVID19 vaccines.

👉 https://t.co/FJFlMpBSSK pic.twitter.com/4SNH7ZpSwz

— World Health Organization (WHO) (@WHO) January 21, 2022

 

---

Resumo técnico da OMS | Aprimorando a resposta à variante Ômicron do SARS-CoV-2.

25 Jan, 2022 | 12:01h

Enhancing response to Omicron SARS-CoV-2 variant – World Health Organization

---

Conselheiros da OMS analisam os reforços das vacinas contra COVID-19 e a vacina da Pfizer para crianças pequenas.

25 Jan, 2022 | 12:00h

WHO advisers weigh in on COVID-19 boosters, Pfizer vaccine in younger kids – CIDRAP

Ver também: Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing – World Health Organization

---